Literature DB >> 32184974

Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands.

Hyejin Park1, Aarti N Urs2, Joseph Zimmerman2, Chuan Liu1, Qiu Wang1, Nikhil M Urs2.   

Abstract

Loss of dopamine neurons is central to the manifestation of Parkinson's disease motor symptoms. The dopamine precursor L-DOPA, the most commonly used therapeutic agent for Parkinson's disease, can restore normal movement yet cause side-effects such as dyskinesias upon prolonged administration. Dopamine D1 and D2 receptors activate G-protein- and arrestin-dependent signaling pathways that regulate various dopamine-dependent functions including locomotion. Studies have shown that shifting the balance of dopamine receptor signaling toward the arrestin pathway can be beneficial for inducing normal movement, while reducing dyskinesias. However, simultaneous activation of both D1 and D2Rs is required for robust locomotor activity. Thus, it is desirable to develop ligands targeting both D1 and D2Rs and their functional selectivity. Here, we report structure-functional-selectivity relationship (SFSR) studies of novel apomorphine analogs to identify structural motifs responsible for biased activity at both D1 and D2Rs.
Copyright © 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 32184974      PMCID: PMC7074212          DOI: 10.1021/acsmedchemlett.9b00575

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  37 in total

Review 1.  Functional selectivity and classical concepts of quantitative pharmacology.

Authors:  Jonathan D Urban; William P Clarke; Mark von Zastrow; David E Nichols; Brian Kobilka; Harel Weinstein; Jonathan A Javitch; Bryan L Roth; Arthur Christopoulos; Patrick M Sexton; Keith J Miller; Michael Spedding; Richard B Mailman
Journal:  J Pharmacol Exp Ther       Date:  2006-06-27       Impact factor: 4.030

Review 2.  Advances in development of dopaminergic aporphinoids.

Authors:  Ao Zhang; Yi Zhang; Alan R Branfman; Ross J Baldessarini; John L Neumeyer
Journal:  J Med Chem       Date:  2007-01-25       Impact factor: 7.446

3.  Diester derivatives as apomorphine prodrugs.

Authors:  R J Borgman; R J Baldessarini; K G Walton
Journal:  J Med Chem       Date:  1976-05       Impact factor: 7.446

Review 4.  Signalling bias in new drug discovery: detection, quantification and therapeutic impact.

Authors:  Terry Kenakin; Arthur Christopoulos
Journal:  Nat Rev Drug Discov       Date:  2012-02-15       Impact factor: 84.694

5.  Relation between the action of dopamine and apomorphine and their O-methylated derivatives upon the CNS.

Authors:  A M Ernst
Journal:  Psychopharmacologia       Date:  1965-05-21

Review 6.  Dopamine receptor pharmacology.

Authors:  P Seeman; H H Van Tol
Journal:  Trends Pharmacol Sci       Date:  1994-07       Impact factor: 14.819

7.  Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias.

Authors:  M A Delfino; A V Stefano; J E Ferrario; I R E Taravini; M G Murer; O S Gershanik
Journal:  Behav Brain Res       Date:  2004-07-09       Impact factor: 3.332

8.  Aporphine enantiomers. Interactions with D-1 and D-2 dopamine receptors.

Authors:  M E Goldman; J W Kebabian
Journal:  Mol Pharmacol       Date:  1984-01       Impact factor: 4.436

9.  Dopamine D2 receptor binding sites for agonists. A tetrahedral model.

Authors:  P Seeman; M Watanabe; D Grigoriadis; J L Tedesco; S R George; U Svensson; J L Nilsson; J L Neumeyer
Journal:  Mol Pharmacol       Date:  1985-11       Impact factor: 4.436

Review 10.  Apomorphine in patients with Parkinson's disease.

Authors:  D Muguet; E Broussolle; G Chazot
Journal:  Biomed Pharmacother       Date:  1995       Impact factor: 6.529

View more
  1 in total

Review 1.  Targeting β-Arrestins in the Treatment of Psychiatric and Neurological Disorders.

Authors:  Sharonda S Harris; Nikhil M Urs
Journal:  CNS Drugs       Date:  2021-03-02       Impact factor: 5.749

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.